NEK11

NEK11 is a serine/threonine kinase that operates as an effector of the DNA damage and replication checkpoints, coupling upstream checkpoint signaling to the destruction of CDC25A and enforcement of cell-cycle arrest (PMID:19734889, PMID:20090422, PMID:12154088). Its kinase activity is induced by DNA-damaging agents and replication inhibitors in a caffeine-sensitive manner, and loss of catalytic function compromises aphidicolin-induced S-phase arrest, placing NEK11 downstream of ATM/ATR signaling (PMID:12154088). In the G2/M checkpoint, CHK1 directly activates NEK11 by phosphorylating Ser273, and NEK11 in turn directly phosphorylates CDC25A on residues required for beta-TrCP-mediated polyubiquitylation and proteasomal degradation; mechanistically, NEK11 functions as a relay kinase that adds the Ser82 phosphate in the CDC25A DSG motif following CHK1 phosphorylation of Ser76, completing the phosphodegron recognized by beta-TrCP (PMID:19734889, PMID:20090422, PMID:21252624). NEK11 activity is additionally controlled by NEK2A, which interacts with NEK11 at the nucleolus and directly phosphorylates its C-terminal non-catalytic region to relieve an autoinhibitory intramolecular contact between that domain and the N-terminal catalytic domain (PMID:15161910). Consistent with a checkpoint-enforcing role, NEK11 depletion abrogates G2/M arrest after ionizing radiation or irinotecan and shifts cells toward p53-dependent apoptosis, and its splice isoforms shuttle between cytoplasm and nucleus via nuclear import and export signals in the C-terminal non-catalytic domain (PMID:26501353). NEK11 also localizes to meiotic spindles and regulates asymmetric oocyte division (PMID:27150633). A loss-of-function nonsense variant co-segregating with familial melanoma, together with somatic loss of the wild-type allele in a carrier's tumor, links NEK11 to melanoma as a candidate tumor suppressor (PMID:31704778).

1. 2002 Medium

   Established NEK11 as a DNA-damage- and replication-responsive kinase, answering whether this NEK family member participates in checkpoint signaling rather than only mitosis.

   Evidence Molecular cloning, kinase assays with wild-type and kinase-dead (K61R) mutants, caffeine inhibition, and cell-cycle analysis in mammalian cells

   PMID:12154088

   Open questions at the time

   • Direct substrates not identified at this stage
   • Precise upstream activator (ATM vs ATR) not resolved beyond caffeine sensitivity
   • Mechanism connecting NEK11 activity to S-phase arrest unknown
2. 2004 High

   Defined how NEK11 catalytic output is switched on, showing NEK2A phosphorylation relieves an intramolecular autoinhibitory contact in NEK11.

   Evidence Reciprocal co-IP of endogenous proteins, in vitro kinase assays, and domain mapping with deletion/truncation constructs at the nucleolus

   PMID:15161910

   Open questions at the time

   • Phosphorylation sites on NEK11 targeted by NEK2A not precisely mapped
   • Physiological trigger coupling NEK2A-NEK11 activation to checkpoint contexts unclear
   • Relationship between nucleolar activation and downstream CDC25A control not connected
3. 2009 High

   Placed NEK11 in a linear CHK1→NEK11→CDC25A pathway, answering how the G2/M checkpoint triggers CDC25A destruction.

   Evidence shRNA screen, RNAi depletion, in vitro kinase assays, co-IP, proteasome inhibitor experiments, and phosphosite mutagenesis (CHK1 phosphorylates NEK11 Ser273; NEK11 phosphorylates CDC25A)

   PMID:19734889 PMID:20090422

   Open questions at the time

   • Structural basis of NEK11 substrate recognition on CDC25A not resolved
   • Whether NEK2A activation feeds into this CHK1-driven arm not tested
4. 2011 Medium

   Refined the mechanism to a hierarchical phosphorylation relay, clarifying the exact CDC25A residues and division of labor between CHK1 and NEK11/CK1α.

   Evidence In vitro hierarchical phosphorylation assays and CDC25A stabilization upon kinase depletion (CHK1 on Ser76, NEK11/CK1α on Ser82 of the DSG motif)

   PMID:21252624

   Open questions at the time

   • Relative in vivo contributions of NEK11 versus CK1α not quantified
   • Context-dependence of which relay kinase acts not established
5. 2015 Medium

   Connected NEK11 checkpoint function to cell fate and clarified isoform localization control, showing depletion abrogates arrest and promotes p53-dependent apoptosis.

   Evidence Isoform-specific RNAi, flow cytometry, apoptosis assays, and nucleocytoplasmic shuttling analysis in HCT116 cells

   PMID:26501353

   Open questions at the time

   • Signals/regulators governing NLS/NES-driven shuttling not identified
   • Distinct functions of the four splice variants only partly resolved
6. 2016 Medium

   Extended NEK11 function beyond the somatic checkpoint to meiosis, showing a role in asymmetric oocyte division.

   Evidence Immunofluorescence localization to meiotic spindles plus siRNA knockdown producing 2-cell-like eggs in mouse oocytes

   PMID:27150633

   Open questions at the time

   • Molecular substrates of NEK11 at the meiotic spindle not identified
   • Whether checkpoint partners (CHK1/CDC25A) mediate this role unknown
7. 2019 Medium

   Implicated NEK11 as a candidate tumor suppressor, linking loss-of-function to familial melanoma.

   Evidence Whole-exome sequencing and co-segregation in a melanoma pedigree, with functional demonstration of proteasomal degradation of the truncated protein and tumor loss of the wild-type allele

   PMID:31704778

   Open questions at the time

   • Single family; broader genetic replication absent in the corpus
   • Mechanistic link between checkpoint loss and melanoma not directly demonstrated

• How NEK11's nucleolar NEK2A-driven activation, its CHK1-dependent checkpoint role, and its meiotic spindle function are integrated remains unresolved.
• No structural model of NEK11 substrate or activator engagement
• Substrates beyond CDC25A not defined
• Tumor-suppressor mechanism in melanoma not mechanistically tied to checkpoint substrates